"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy—that can miss 16%-40% of existing csPCa—may be difficult to justify for all patients," writes Badar M. Mian, MD.
Other key prostate cancer studies from AUA 2018 included updated survival data from the European Randomized Study of Screening for Prostate Cancer and a multicenter trial of MRI-targeted biopsy.
Apalutamide (Erleada) treatment in men with nonmetastatic castrate-resistant prostate cancer significantly improves metastasis-free survival and does so without adversely affecting health-related quality of life.
“A multivariable analysis confirmed that AR-V7 status independently predicted PSA response,” says researcher Matthias Heck, MD.
"Although we commend the USPSTF for upgrading the recommendation for PSA- and digital rectal exam-based prostate cancer screening from a “D” to a “C” grade (JAMA 2018; 319:1901–13), we believe that not enough emphasis is placed on screening high-risk groups for prostate cancer," write Navin Shah, MD, and Vladimir Ioffe, MD.
Findings from a retrospective analysis of data collected at the National Institutes of Health provide insight on how multiparametric MRI/transrectal ultrasound-fusion biopsy (“fusion biopsy”) may be affecting management patterns and outcomes for men with prostate cancer.
Adding abiraterone acetate (ZYTIGA) to androgen deprivation therapy for the management of patients with metastatic castration-naïve prostate cancer does not increase medical resource utilization.
The treatment method may delay need for systemic therapy in men with oligometastatic prostate cancer.
Study findings bolster the idea that frequent repeat biopsies are unnecessary.
Learn about this and other products in the pipeline for prostate cancer and bladder cancer.